EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Real‐World Effectiveness and 12‐Month Persistence of a Semaglutide‐Supported Digital Weight‐Loss Service: A Retrospective Cohort Study in Germany

Louis Talay, Jason Hom, Marilyn Tan iD, Neera Ahuja

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70916 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Louis Talay und 3 weiteren Autor:innen. Beteiligte Einrichtung: Eucalyptus Health, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Weight Reduction Programs, Obesity, Anti-Obesity Agents. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the 12‐month effectiveness and patient persistence of a semaglutide‐supported digital weight‐loss service (DWLS) in a real‐world German cohort.

Methods

This retrospective study analysed 4535 patients who initiated the Juniper Germany DWLS. Primary endpoints included 12‐month medication and data submission adherence (receiving ≥ 10 orders) and mean weight‐loss percentage. Effectiveness was assessed via a per‐protocol (PP) analysis of an adherent sub‐cohort ( n = 546) and an intention‐to‐treat (ITT) analysis of the full cohort using Last Observation Carried Forward (LOCF) and a Worst‐Case Scenario (WCS) sensitivity model. Binary logistic and multiple linear regressions identified predictors of attrition (churn) and efficacy.

Results

Of the total cohort ( n = 4535), mean 12‐month weight loss was 9.47% (LOCF). However, sensitivity analysis using a WCS model—assuming 0% weight loss for all dropouts—yielded a mean of 2.40%. Among the 12% of patients ( n = 546) who remained adherent to both medication and data submission protocols, mean weight loss was 15.13% (±7.1). Program persistence was significantly bolstered by achieving a healthy BMI milestone (OR = 0.29, p < 0.001), encountering a weight‐loss plateau (OR = 0.41, p < 0.001), and higher baseline obesity severity (Obesity Class I–III: p < 0.023). Conversely, high clinical complexity (≥ 3 comorbidities) more than doubled the risk of churn (OR = 2.12, p = 0.002), while previous GLP‐1 RA use also significantly increased churn risk (OR = 1.57, p = 0.001). While moderate early engagement (2–10 logs) was a strong predictor of persistence ( p < 0.001), intensive tracking (> 10 logs) did not significantly reduce churn risk ( p = 0.393).

Conclusion

The population‐level impact of this DWLS is fundamentally limited by high attrition (88%) in an unsubsidised environment. While significant weight loss is possible for a non‐representative adherent minority, the mean effectiveness for the total initiating population (2.40% WCS) highlights that real‐world success is strictly conditional upon long‐term persistence. The study found that both clinical success and setbacks were associated with program adherence. It also observed that patients of high clinical complexity were at greater risk of attrition. Finally, it found that high‐friction manual weight logging serves as a marker of commitment rather than anxiety as had been reported in app‐based DWLSs where tracking has significantly lower friction. These findings suggest that the predictive value of digital engagement is fundamentally shaped by DWLS delivery mode and the behavioural cost of engagement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesWeight Reduction ProgramsObesityAnti-Obesity AgentsHumansSemaglutideRetrospective StudiesFemaleMaleGermanyMiddle AgedWeight LossTreatment OutcomeAgedAdultDiabetes Mellitus, Type 2Digital HealthDigital Media

Stichwörter der Autor:innen

antiobesity drugcohort studyobesity carereal‐world evidencesemaglutideweight management

Substanzen

SemaglutideGlucagon-Like PeptidesAnti-Obesity Agents

Autor:innen und Institutionen

  • Eucalyptus Health, Sydney, New South Wales, Australia.
  • Department of Medicine, Stanford University Medical Centre, Stanford, California, USA.

ORCID-Profile: Marilyn Tan

Zitieren

APA

Talay, L., Hom, J., Tan, M., & Ahuja, N. (2026). Real‐World Effectiveness and 12‐Month Persistence of a Semaglutide‐Supported Digital Weight‐Loss Service: A Retrospective Cohort Study in Germany. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70916

Vancouver

Talay L, Hom J, Tan M, Ahuja N. Real‐World Effectiveness and 12‐Month Persistence of a Semaglutide‐Supported Digital Weight‐Loss Service: A Retrospective Cohort Study in Germany. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70916

BibTeX
@article{Talay2026,
  author = {Talay, Louis and Hom, Jason and Tan, Marilyn and Ahuja, Neera},
  title = {Real‐World Effectiveness and 12‐Month Persistence of a Semaglutide‐Supported Digital Weight‐Loss Service: A Retrospective Cohort Study in Germany},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70916}
}
Kostenlos starten →